First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic ...
The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number ...
Luke Coutinho mentions Vitamin D3 is a hormone that activates killer immune cells (NK, T-cells), calms dangerous inflammation ...
A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...
Investigators conducted this phase III trial to determine whether immunotherapy was more effective when administered early in the day.
Zinc and vitamin A together can produce a synergistic effect to improve vision, immunity and other vital functions.
The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with NSCLC, RCC, colorectal cancer ...
A three-day retreat at Poomaale Estate, Coorg, was a masterclass in doing nothing — except forest bathing, the art of soaking in nature, not just looking.
Early Phase 2a data suggest the IPF therapy GRI-0621 alters gene activity tied to inflammation, scarring, and tissue repair.
Diet and plant-derived bioactives are now recognized as active regulators of immune tone that link chronic metabolic dysfunction to cancer initiation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results